{
    "name": "duloxetine",
    "comment": "Rx",
    "other_names": [
        "Cymbalta",
        "Irenka",
        "Drizalma Sprinkle"
    ],
    "classes": [
        "Antidepressants",
        "SNRIs",
        "Fibromyalgia Agents"
    ],
    "source": "https://reference.medscape.com/drug/cymbalta-irenka-duloxetine-342960",
    "pregnancy": {
        "common": [
            "Data from a postmarketing retrospective cohort study indicate that use in the month before delivery may be associated with an increased risk of postpartum hemorrhage; data from published literature and from a postmarketing retrospective cohort study have not identified a clear drug-associated risk of major birth defects or other adverse developmental outcomes; there are risks associated with untreated depression in pregnancy and with exposure to SNRIs and SSRIs, during pregnancy",
            "Women who discontinued antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continued antidepressants; consider risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum",
            "Pregnant women with fibromyalgia are at increased risk for adverse maternal and infant outcomes including preterm premature rupture of membranes, preterm birth, small for gestational age, intrauterine growth restriction, placental disruption, and venous thrombosis; not known if adverse maternal and fetal outcomes are a direct result of fibromyalgia or other comorbid factors"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "  ",
                    "  ",
                    "In animal studies with duloxetine, fetal weights were decreased but there was no evidence of teratogenicity in pregnant rats and rabbits at oral doses administered during organogenesis up to 4 and 7 times the maximum recommended human dose (MRHD) of 120 mg/day",
                    "When duloxetine was administered orally to pregnant rats throughout gestation and lactation, pup weights at birth and pup survival to 1 day postpartum were decreased at a dose 2 times the MRHD",
                    "  ",
                    "  ",
                    "In rats and rabbits treated with duloxetine during organogenesis, fetal weights decreased but there was no evidence of developmental effects at doses up to 3 and 6 times, respectively, the MRHD of 120 mg/day given to adolescents on a mg/m",
                    " basis",
                    "When oral duloxetine was administered to pregnant rats throughout gestation and lactation, pup weights at birth and pup survival to 1 day postpartum were decreased at a dose 2 times the MRHD given to adolescents on a mg/m",
                    " basis",
                    "For both formulations, pup behaviors consistent with increased reactivity, such as increased startle response to noise and decreased habituation of locomotor activity were observed",
                    "Postweaning growth was not adversely affected",
                    "Use in pregnancy only if the potential benefit justifies the potential risk to the fetus"
                ]
            },
            {
                "type": "Pregnancy registry",
                "description": [
                    "Pregnancy registry monitors the pregnancy outcomes in women exposed during pregnancy",
                    "Cymbalta: Contact pregnancy registry at 1-866-814-6975 or ",
                    "Drizalma Sprinkle: Contact the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at "
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Neonates exposed during pregnancy to serotonin - norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding which can arise immediately upon delivery",
                    "Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying",
                    "These features are consistent with either a direct toxic effect of the SNRIs or SSRIs, or possibly, a drug discontinuation syndrome",
                    "In some cases, the clinical picture is consistent with serotonin syndrome"
                ]
            },
            {
                "type": "Cymbalta",
                "description": [
                    "Drug present in human milk in a published study, lactating women who were weaning their infants were given duloxetine",
                    "At steady state, duloxetine concentration in breast milk was ~25% that of maternal plasma",
                    "Estimated daily infant dose was ~0.14% of the maternal dose",
                    "Exercise caution when administering to a nursing woman"
                ]
            },
            {
                "type": "Drizalma Sprinkle",
                "description": [
                    "Data from the published literature report the presence of duloxetine in human milk",
                    "There are reports of sedation, poor feeding, and poor weight gain in infants exposed to duloxetine through breast milk",
                    "There are no data on effect of duloxetine on milk production",
                    "Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition",
                    "Women given 40 mg of duloxetine PO BID for 3.5 days; peak concentration measured in breast milk occurred at a median of 3 hrs post-dose",
                    "Amount of duloxetine in breast milk was ~7 mcg/day while on that dose; estimated daily infant dose was ~2 mcg/kg/day, which is <1% of the maternal dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Suicidal thoughts and behaviors",
                    "description": [
                        "Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies",
                        "These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients >24 yr",
                        "There was a reduction in risk with antidepressant use in patients ≥65 yr",
                        "In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors",
                        "Advise families and caregivers of the need for close observation and communication with the prescriber"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Concomitant use of duloxetine with MAOIs intended to treat psychiatric disorders",
                "Use of duloxetine within 14 days of MAOI discontinuation",
                "Initiating duloxetine in patients who are being treated with linezolid or IV methylene blue"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Prior to initiating treatment with, screen patients for any personal or family history of bipolar disorder, mania, or hypomania",
                "Suicidality; monitor for clinical worsening and suicide risk, especially in children, adolescents and young adults (18-24 years) during early phases of treatment and alterations in dosage (see Black Box Warnings)",
                "Serotonin syndrome or neuroleptic malignant syndrome-like reactions may occur; discontinue and initiate supportive therapy; closely monitor patients concomitantly receiving triptans, antipsychotics and serotonin precursors",
                "Neonates exposed to serotonin-norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) late in 3rd trimester of pregnancy have developed complications necessitating prolonged hospitalization, respiratory support, and tube feeding",
                "Increased risk of hepatotoxicity, sometimes fatal; monitor for abdominal pain, hepatomegaly, elevated AST/ALT exceeding 20x ULN, and jaundice; cholestatic jaundice with minimal elevations of hepatic transaminases have also been reported; not recommended in patients with substantial alcohol use or chronic liver disease",
                "SSRIs and SNRIs may impair platelet aggregation and increase the risk of bleeding events, ranging from ecchymoses, hematomas, epistaxis, petechiae, and GI hemorrhage to life-threatening hemorrhage; concomitant use of aspirin, NSAIDs, warfarin, other anticoagulants, or other drugs known to affect platelet function may add to this risk",
                "Severe skin reactions (eg, erythema multiforme and Stevens-Johnson syndrome); discontinue at first appearance of blisters, peeling rash, mucosal erosions, or any other sign of hypersensitivity if no other etiology can be identified",
                "Orthostatic hypotension and syncope, especially during week 1 of therapy; monitor patients taking drugs that increase risk of orthostatic hypotension; consider dose reduction or discontinue therapy in patients who experience symptomatic orthostatic hypotension, falls and/or syncope",
                "Hyponatremia due to syndrome of inappropriate antidiuretic hormone (SIADH); cases of serum sodium <110 mmol/L have been reported to be reversible upon discontinuance",
                "Diabetes due to worsening of glycemic control in some patients; monitor increases in fasting blood glucose and hemoglobin A1c",
                "Monitor weight and growth in adolescents and children; decrease in appetite and weight loss reported",
                "Urinary hesitation and retention",
                "Cognitive or motor function impairment; use with caution when operating heavy machinery",
                "Bone fractures reported with antidepressant treatment; consider possibility of bone fracture if patient complains of unexplained bone pain or joint tenderness or experiences bruising or swelling",
                "Use caution in gastroparesis, hypertension, controlled narrow-angle glaucoma, renal impairment, or seizure disorders",
                "May lower seizure threshold when administered on currently with other drugs that lower seizure threshold",
                "Risk of mydriasis; may trigger angle closure attack in patients with angle-closure glaucoma with anatomically narrow angles without a patent iridectomy",
                "Headache, dizziness, nausea, diarrhea, paresthesia, vomiting, irritability, insomnia, hyperhidrosis, anxiety, and fatigue reported in patients following abrupt discontinuation of duloxetine",
                "Therapy may increase blood pressure; measure blood prior to initiating treatment and periodically throughout treatment",
                "Use with caution in patients with conditions that slow gastric emptying"
            ],
            "specific": [
                {
                    "type": "Sexual dysfunction",
                    "description": [
                        "Use may cause symptoms of sexual dysfunction in both male and female patients; inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider",
                        "Use of SSRIs, may cause symptoms of sexual dysfunction; in male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction",
                        "Changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of psychiatric disorders or diabetes, but may also be a consequence of pharmacologic treatment",
                        "Use of SNRIs, may cause symptoms of sexual dysfunction; in male patients, SNRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction; in female patients, SNRI use may result in decreased libido and delayed or absent orgasm",
                        "It is important for prescribers to inquire about sexual function prior to initiation of therapy and to inquire specifically about changes in sexual function during treatment; sexual function may not be spontaneously reported",
                        "When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder",
                        "Discuss potential management strategies to support patients in making informed decisions about treatment"
                    ]
                },
                {
                    "type": "Increased risk of bleeding postpartum",
                    "description": [
                        "Drugs that interfere with serotonin reuptake inhibition, may increase risk of bleeding; case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and occurrence of gastrointestinal bleeding",
                        "A postmarketing study showed a higher incidence of postpartum hemorrhage in mothers receiving therapy;",
                        "Other bleeding events related to SSRI and SNRI use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages; concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk",
                        "Inform about risk of bleeding associated with concomitant use of drug and NSAIDs, aspirin, or other drugs that affect coagulation"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Use caution when administering concomitantly with CNS depressants ",
                        "Duloxetine is CYP1A2 and CYP2D6 substrate; moderate CYP2D6 inhibitor",
                        "CYP2D6 Inhibitors",
                        "Concomitant use of duloxetine with potent CYP2D6 inhibitors may result in higher concentrations (on average of 60%) of duloxetine",
                        "Coadministration of duloxetine with drugs that are extensively metabolized by CYP2D6 with a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs]), phenothiazines and Type 1C antiarrhythmics (eg, propafenone, flecainide), should be used with caution",
                        "Avoid coadministration with Drizalma Sprinkle and potent CYP2D6",
                        "Alcohol",
                        "Cymbalta: Three treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction; substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen",
                        "Drizalma Sprinkle: An in vitro study showed significant increases of duloxetine hydrochloride release at 2 hr to ~86% and 56% of the drug release in the presence of 40% and 20% alcohol, respectively",
                        "Serotonergic drugs",
                        "Development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including duloxetine, when administered concomitantly with other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)",
                        "If concomitant use with other serotonergic drugs is clinically warranted, advise patients of potential risk for serotonin syndrome, particularly during treatment initiation and dose increases; treatment with concomitant serotonergic agents, should be discontinued immediately if above events occur and initiate supportive symptomatic treatment "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "duloxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "iobenguane I 123",
            "description": {
                "common": "duloxetine decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid and duloxetine both increase  serotonin levels. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine and duloxetine both increase  serotonin levels. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine and duloxetine both increase  serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "safinamide",
            "description": {
                "common": "duloxetine, safinamide.\nEither increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline and duloxetine both increase  serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine and duloxetine both increase  serotonin levels. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "duloxetine and amitriptyline both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amoxapine",
            "description": {
                "common": "duloxetine and amoxapine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "duloxetine and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bupropion",
            "description": {
                "common": "duloxetine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buspirone",
            "description": {
                "common": "duloxetine and buspirone both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cigarette smoking",
            "description": {
                "common": "cigarette smoking will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clomipramine",
            "description": {
                "common": "duloxetine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "duloxetine and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dacomitinib",
            "description": {
                "common": "dacomitinib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desipramine",
            "description": {
                "common": "duloxetine and desipramine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "duloxetine and desvenlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "duloxetine will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dolasetron",
            "description": {
                "common": "dolasetron, duloxetine.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dosulepin",
            "description": {
                "common": "duloxetine and dosulepin both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxepin",
            "description": {
                "common": "duloxetine and doxepin both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "givosiran",
            "description": {
                "common": "givosiran will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "granisetron",
            "description": {
                "common": "granisetron, duloxetine.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imipramine",
            "description": {
                "common": "duloxetine and imipramine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iobenguane I 131",
            "description": {
                "common": "duloxetine will decrease the level or effect of iobenguane I 131 by  Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid leniolisib with CYP1A2 substrates that have a narrow therapeutic index"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "duloxetine and levomilnacipran both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofepramine",
            "description": {
                "common": "duloxetine and lofepramine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "duloxetine and lorcaserin both increase  sedation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maprotiline",
            "description": {
                "common": "duloxetine and maprotiline both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meperidine",
            "description": {
                "common": "duloxetine and meperidine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylene blue",
            "description": {
                "common": "methylene blue and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactions"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "duloxetine, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mexiletine",
            "description": {
                "common": "mexiletine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "milnacipran",
            "description": {
                "common": "duloxetine and milnacipran both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "modafinil",
            "description": {
                "common": "modafinil will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "duloxetine and nefazodone both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "netupitant/palonosetron, duloxetine.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "duloxetine and nortriptyline both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "duloxetine and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ondansetron",
            "description": {
                "common": "ondansetron, duloxetine.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod increases toxicity of duloxetine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palonosetron",
            "description": {
                "common": "palonosetron, duloxetine.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pefloxacin",
            "description": {
                "common": "pefloxacin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phentermine",
            "description": {
                "common": "duloxetine, phentermine.\nEither increases toxicity of the other by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pipemidic acid",
            "description": {
                "common": "pipemidic acid will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pirfenidone",
            "description": {
                "common": "duloxetine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protriptyline",
            "description": {
                "common": "duloxetine and protriptyline both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "duloxetine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rasagiline",
            "description": {
                "common": "rasagiline and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b and duloxetine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smoking",
            "description": {
                "common": "smoking will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "duloxetine and St John's Wort both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tedizolid",
            "description": {
                "common": "tedizolid, duloxetine.\nEither increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioridazine",
            "description": {
                "common": "duloxetine will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tobacco use",
            "description": {
                "common": "tobacco use will decrease the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tramadol",
            "description": {
                "common": "duloxetine will increase the level or effect of tramadol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trazodone",
            "description": {
                "common": "duloxetine and trazodone both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trimipramine",
            "description": {
                "common": "duloxetine and trimipramine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "duloxetine and venlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilazodone",
            "description": {
                "common": "duloxetine, vilazodone.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "duloxetine, vortioxetine.\nEither increases effects of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zileuton",
            "description": {
                "common": "zileuton will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "5-HTP",
            "description": {
                "common": "duloxetine and 5-HTP both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abiraterone",
            "description": {
                "common": "abiraterone increases levels of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "duloxetine, aceclofenac.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "duloxetine, acemetacin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "almotriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, duloxetine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "duloxetine, aspirin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "duloxetine, aspirin rectal.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "duloxetine, aspirin/citric acid/sodium bicarbonate.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "duloxetine increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "duloxetine, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "duloxetine will increase the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone [benzhydrocodone is prodrug of hydrocodone]) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "duloxetine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "duloxetine, buprenorphine subdermal implant.\nEither increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "duloxetine, buprenorphine, long-acting injection.\nEither increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol, duloxetine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "captopril increases effects of duloxetine by pharmacodynamic synergism. Use Caution/Monitor. Blood pressure lowering drugs may enhance the hypotensive effect of duloxetine. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate, duloxetine.\nEither increases effects of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "duloxetine, choline magnesium trisalicylate.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Coadministration of CYP1A2 inhibiting quinolones with duloxetine may lead to significant increases in duloxetine levels, AUC, and half-life. Consider therapy modification if duloxetine is necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clobazam will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "duloxetine increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SNRIs affect platelet activation; coadministration of SNRIs with clopidogrel may increase the risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "duloxetine and cocaine topical both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "duloxetine decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "cyproheptadine decreases effects of duloxetine by pharmacodynamic antagonism. Use Caution/Monitor. Cyproheptadine may diminish the serotonergic effect of SNRIs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "duloxetine and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox increases levels of duloxetine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "duloxetine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "desvenlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "duloxetine and dexfenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "duloxetine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine transdermal",
            "description": {
                "common": "duloxetine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "diazepam intranasal, duloxetine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and duloxetine both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "duloxetine, diclofenac.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and duloxetine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "duloxetine, diflunisal.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "duloxetine and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "duloxetine and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "eletriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "duloxetine increases levels of eluxadoline by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP1A2 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "duloxetine and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "duloxetine and escitalopram both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole will decrease the level or effect of duloxetine by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol, duloxetine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hepatotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "duloxetine, etodolac.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenbufen",
            "description": {
                "common": "duloxetine, fenbufen.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "duloxetine and fenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "duloxetine, fenoprofen.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "duloxetine will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fish oil triglycerides",
            "description": {
                "common": "fish oil triglycerides will increase the level or effect of duloxetine by  anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "duloxetine, flurbiprofen.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "frovatriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin, duloxetine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil, duloxetine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "duloxetine and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea, duloxetine. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "duloxetine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "duloxetine will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib will increase the level or effect of duloxetine by  anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "duloxetine, ibuprofen.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "duloxetine, ibuprofen IV.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "duloxetine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "duloxetine, indomethacin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "duloxetine, ketoprofen.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "duloxetine, ketorolac.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "duloxetine, ketorolac intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "L-tryptophan",
            "description": {
                "common": "duloxetine and L-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, duloxetine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant, duloxetine.\nEither increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "duloxetine, lisdexamfetamine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "duloxetine and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "duloxetine will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "lorcaserin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "duloxetine, lornoxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lsd",
            "description": {
                "common": "duloxetine and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, duloxetine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "duloxetine, meclofenamate.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "duloxetine, mefenamic acid.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "duloxetine, meloxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "duloxetine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "duloxetine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "duloxetine will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, duloxetine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirabegron",
            "description": {
                "common": "mirabegron will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "duloxetine and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "duloxetine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "duloxetine, nabumetone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "duloxetine, naproxen.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naratriptan",
            "description": {
                "common": "naratriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "duloxetine will increase the level or effect of nebivolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "duloxetine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "duloxetine will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "duloxetine, oxaprozin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "duloxetine will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "duloxetine will increase the level or effect of oxymorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "parecoxib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2b",
            "description": {
                "common": "peginterferon alfa 2b, duloxetine. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentazocine",
            "description": {
                "common": "duloxetine and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentoxifylline",
            "description": {
                "common": "duloxetine will increase the level or effect of pentoxifylline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "duloxetine, piroxicam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "pregabalin, duloxetine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "duloxetine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "duloxetine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinacrine",
            "description": {
                "common": "quinacrine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "remifentanil",
            "description": {
                "common": "remifentanil increases toxicity of duloxetine by serotonin levels. Modify Therapy/Monitor Closely. Increases risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "remimazolam",
            "description": {
                "common": "remimazolam, duloxetine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "duloxetine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "duloxetine increases toxicity of rivaroxaban by anticoagulation. Use Caution/Monitor. May enhance the antiplatelet effect of nonsteroidal anti-inflammatory agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "rizatriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rolapitant",
            "description": {
                "common": "rolapitant will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "duloxetine, salicylates (non-asa).\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "duloxetine, salsalate.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "SAMe",
            "description": {
                "common": "duloxetine and SAMe both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "duloxetine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. \nComment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, duloxetine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "sufentanil SL, duloxetine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "duloxetine, sulfasalazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "duloxetine, sulindac.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "sumatriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "sumatriptan intranasal and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "duloxetine decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "duloxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "duloxetine and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbinafine",
            "description": {
                "common": "terbinafine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teriflunomide",
            "description": {
                "common": "teriflunomide decreases levels of duloxetine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "duloxetine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "duloxetine, tolfenamic acid.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "duloxetine, tolmetin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "duloxetine and tramadol both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valerian",
            "description": {
                "common": "valerian and duloxetine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "duloxetine, vorapaxar.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "duloxetine, warfarin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serotonin release by platelets plays an important role in hemostasis. SSRIs and SNRIs may increase anticoagulation effect of warfarin. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "zolmitriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "almotriptan",
            "description": {
                "common": "duloxetine, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "duloxetine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "bumetanide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carvedilol",
            "description": {
                "common": "duloxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celandine",
            "description": {
                "common": "celandine decreases effects of duloxetine by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "duloxetine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "duloxetine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "dexmethylphenidate increases effects of duloxetine by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "duloxetine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxepin",
            "description": {
                "common": "duloxetine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eletriptan",
            "description": {
                "common": "duloxetine, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "encainide",
            "description": {
                "common": "duloxetine will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "ethacrynic acid, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "ethinylestradiol will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flecainide",
            "description": {
                "common": "duloxetine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "duloxetine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "duloxetine will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "duloxetine, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "furosemide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "galantamine",
            "description": {
                "common": "duloxetine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "haloperidol",
            "description": {
                "common": "duloxetine will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iloperidone",
            "description": {
                "common": "duloxetine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lithium",
            "description": {
                "common": "duloxetine, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loratadine",
            "description": {
                "common": "duloxetine will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "naratriptan",
            "description": {
                "common": "duloxetine, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "panax ginseng",
            "description": {
                "common": "panax ginseng increases effects of duloxetine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paroxetine",
            "description": {
                "common": "duloxetine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perhexiline",
            "description": {
                "common": "duloxetine will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perphenazine",
            "description": {
                "common": "duloxetine will increase the level or effect of perphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pleurisy root",
            "description": {
                "common": "pleurisy root decreases effects of duloxetine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "duloxetine will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promazine",
            "description": {
                "common": "duloxetine will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promethazine",
            "description": {
                "common": "duloxetine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "duloxetine, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "serdexmethylphenidate/dexmethylphenidate increases effects of duloxetine by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "duloxetine, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "duloxetine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolterodine",
            "description": {
                "common": "duloxetine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "torsemide",
            "description": {
                "common": "torsemide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "duloxetine will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tropisetron",
            "description": {
                "common": "duloxetine will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "duloxetine, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "23-25"
        },
        {
            "name": "Dry mouth",
            "percent": "13-15"
        },
        {
            "name": "Headache",
            "percent": "13-14"
        },
        {
            "name": "Somnolence",
            "percent": "10-12"
        },
        {
            "name": "Fatigue",
            "percent": "9-11"
        },
        {
            "name": "Constipation",
            "percent": "9-10"
        },
        {
            "name": "Dizziness",
            "percent": "9-10"
        },
        {
            "name": "Insomnia",
            "percent": "9-10"
        },
        {
            "name": "Diarrhea",
            "percent": "9-10"
        },
        {
            "name": "Anorexia",
            "percent": "8"
        },
        {
            "name": "Decreased appetite",
            "percent": "7-8"
        },
        {
            "name": "Abdominal pain",
            "percent": "4-6"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "6"
        },
        {
            "name": "Agitation",
            "percent": "5"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "5"
        },
        {
            "name": "Vomiting",
            "percent": "3-5"
        },
        {
            "name": "Male sexual dysfunction",
            "percent": "2-5"
        },
        {
            "name": "Erectile dysfunction",
            "percent": "4"
        },
        {
            "name": "Decreased libido",
            "percent": "4"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "4"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "4"
        },
        {
            "name": "URTI",
            "percent": "3-4"
        },
        {
            "name": "Decreased libido",
            "percent": "3-4"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "2-3"
        },
        {
            "name": "Abnormal orgasm",
            "percent": "3"
        },
        {
            "name": "Agitation",
            "percent": "3"
        },
        {
            "name": "Anxiety",
            "percent": "3"
        },
        {
            "name": "Blurred vision",
            "percent": "3"
        },
        {
            "name": "Cough",
            "percent": "3"
        },
        {
            "name": "Influenza",
            "percent": "2-3"
        },
        {
            "name": "Muscle spasms",
            "percent": "3"
        },
        {
            "name": "Tremor",
            "percent": "2"
        },
        {
            "name": "Abnormal dreams",
            "percent": "2"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        },
        {
            "name": "Hot flushes",
            "percent": "2"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "2"
        },
        {
            "name": "Palpitations",
            "percent": "2"
        },
        {
            "name": "Paresthesia",
            "percent": "2"
        },
        {
            "name": "Weight loss",
            "percent": "2"
        },
        {
            "name": "Yawning",
            "percent": "2"
        },
        {
            "name": "Blood pressure increase",
            "percent": "2"
        },
        {
            "name": "Ejaculation delayed",
            "percent": "1"
        },
        {
            "name": "Dysuria",
            "percent": "1"
        },
        {
            "name": "Gastritis",
            "percent": "1"
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "General",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction",
            "percent": null
        },
        {
            "name": "angioneurotic edema",
            "percent": null
        },
        {
            "name": "hypersensitivity",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "rigors",
            "percent": null
        },
        {
            "name": "falls",
            "percent": null
        },
        {
            "name": "feeling abnormal",
            "percent": null
        },
        {
            "name": "feeling hot and",
            "percent": null
        },
        {
            "name": "or cold",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "thirst",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Hypertensive crisis",
            "percent": null
        },
        {
            "name": "supraventricular arrhythmia",
            "percent": null
        },
        {
            "name": "myocardial infarction",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "Takotsubo cardiomyopathy",
            "percent": null
        },
        {
            "name": "Endocrine",
            "percent": null
        },
        {
            "name": "Galactorrhea",
            "percent": null
        },
        {
            "name": "gynecologic bleeding",
            "percent": null
        },
        {
            "name": "hyperglycemia",
            "percent": null
        },
        {
            "name": "hyperprolactinemia",
            "percent": null
        },
        {
            "name": "hypothyroidism",
            "percent": null
        },
        {
            "name": "Neurologic",
            "percent": null
        },
        {
            "name": "Restless legs syndrome",
            "percent": null
        },
        {
            "name": "seizures upon treatment discontinuance",
            "percent": null
        },
        {
            "name": "extrapyramidal disorders",
            "percent": null
        },
        {
            "name": "dysgeusia",
            "percent": null
        },
        {
            "name": "lethargy",
            "percent": null
        },
        {
            "name": "and paraesthesia",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "disturbance in attention",
            "percent": null
        },
        {
            "name": "dyskinesia",
            "percent": null
        },
        {
            "name": "myoclonus",
            "percent": null
        },
        {
            "name": "poor quality sleep",
            "percent": null
        },
        {
            "name": "Ophthalmic",
            "percent": null
        },
        {
            "name": "Glaucoma",
            "percent": null
        },
        {
            "name": "blurred vision",
            "percent": null
        },
        {
            "name": "diplopia",
            "percent": null
        },
        {
            "name": "dry eyes",
            "percent": null
        },
        {
            "name": "visual impairment",
            "percent": null
        },
        {
            "name": "Otic",
            "percent": null
        },
        {
            "name": "Tinnitus",
            "percent": null
        },
        {
            "name": "upon treatment discontinuance",
            "percent": null
        },
        {
            "name": "ear pain",
            "percent": null
        },
        {
            "name": "vertigo",
            "percent": null
        },
        {
            "name": "Psychiatric",
            "percent": null
        },
        {
            "name": "Aggression and anger",
            "percent": null
        },
        {
            "name": "particularly early in treatment or after treatment discontinuance",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "abnormal dreams and sleep disorder",
            "percent": null
        },
        {
            "name": "apathy",
            "percent": null
        },
        {
            "name": "bruxism",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        },
        {
            "name": "confusional state",
            "percent": null
        },
        {
            "name": "irritability",
            "percent": null
        },
        {
            "name": "mood swings",
            "percent": null
        },
        {
            "name": "and suicide attempt",
            "percent": null
        },
        {
            "name": "completed suicide",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Musculoskeletal",
            "percent": null
        },
        {
            "name": "Trismus",
            "percent": null
        },
        {
            "name": "muscle spasm",
            "percent": null
        },
        {
            "name": "muscle tightness",
            "percent": null
        },
        {
            "name": "muscle twitching",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Serious skin reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "erythema multiforme and Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "necessitating drug discontinuance or hospitalization",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "dermatitis",
            "percent": null
        },
        {
            "name": "cold sweat",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "increased tendency to bruise",
            "percent": null
        },
        {
            "name": "night sweats",
            "percent": null
        },
        {
            "name": "photosensitivity reaction",
            "percent": null
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "microscopic or unspecified",
            "percent": null
        },
        {
            "name": "cutaneous vasculitis",
            "percent": null
        },
        {
            "name": "sometimes associated with systemic involvement",
            "percent": null
        },
        {
            "name": "acute pancreatitis",
            "percent": null
        },
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "Gastroenteritis",
            "percent": null
        },
        {
            "name": "laryngitis",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Increased",
            "percent": null
        },
        {
            "name": "decreased weight",
            "percent": null
        },
        {
            "name": "increased blood cholesterol",
            "percent": null
        }
    ]
}